D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.